Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
41 hedge funds and large institutions have $49.5M invested in Merrimack Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
68% more capital invested
Capital invested by funds: $29.5M → $49.5M (+$19.9M)
8% more funds holding
Funds holding: 38 → 41 (+3)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
75% less call options, than puts
Call options by funds: $276K | Put options by funds: $1.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$1.22M |
| 2 |
NM
Newtyn Management
New York
|
+$925K |
| 3 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
+$229K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$212K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$85.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$299K |
| 2 |
Renaissance Technologies
New York
|
-$76K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$48.6K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$34.9K |
| 5 |
Two Sigma Investments
New York
|
-$29.4K |
MACK Hedge Fund Activity: Q1 2022 in Review
41 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2022, worth a combined $49.5M — up 68% from $29.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MACK positions and 1 closed out — a net gain of 3 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Sepio Capital, adding an estimated $1.22M. The largest seller was Nantahala Capital Management, cutting an estimated $299K.
- 41 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2022, up from 38 in Q4 2021.
- Funds reported $49.5M of Merrimack Pharmaceuticals, Inc. stock for Q1 2022, up 68% quarter-over-quarter.
- 4 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2022 and 1 closed out, a net change of +3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2022 was Sepio Capital, an estimated $1.22M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2022 was Nantahala Capital Management, an estimated $299K sold.
Based on aggregated 13F filings for Q1 2022.